GlassScriptPhysician profile
Deidra Ann Duncan
NPI 1356701080
$2,651.83
in general payments reported to CMS, 2019-2025
25 companies · $327 in 2025
The $327 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $341 · 2021: $643 · 2022: $369 · 2023: $387 · 2024: $307 · 2025: $327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $935 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.49 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $427.23 | 2019-2023 | Liletta |
| Astellas Pharma US INC | $306.67 | 2021-2025 | Veozah |
| Mayne Pharma Commercial LLC | $285.12 | 2021-2025 | |
| Exeltis, USA INC. | $263.97 | 2020-2025 | Slynd |
| Coopersurgical, INC. | $199.16 | 2020-2024 | Paragard T 380a |
| Hologic Sales and Service, LLC | $160.85 | 2023-2025 | Aptima |
| Davol INC. | $106.39 | 2020 | |
| Amag Pharmaceuticals, INC. | $102.45 | 2019 | |
| Pfizer INC. | $97.51 | 2021-2025 | |
| Intuitive Surgical, INC. | $97.16 | 2021 | |
| Merck Sharp & Dohme LLC | $94.79 | 2021-2023 | Gardasil 9 |
| Evofem Biosciences, INC. | $89.98 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $80.71 | 2023-2025 | Myfembree |
| Myovant Sciences INC. | $68.17 | 2021-2022 | |
| Organon LLC | $63.30 | 2022-2023 | Nexplanon |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $32.85 | 2022-2025 | |
| Daiichi Sankyo INC. | $30.20 | 2020-2022 | |
| Agile Therapeutics, INC. | $28.18 | 2021-2022 | |
| Baxter Healthcare | $24.39 | 2021 | |
| Biogen, INC. | $22.98 | 2025 | Zurzuvae |
| Novo Nordisk INC | $18.59 | 2025 | Wegovy |
| Cumberland Pharmaceuticals, INC. | $13.78 | 2020 | |
| Avion Pharmaceuticals | $13.66 | 2021 | |
| Currax Pharmaceuticals LLC | $12.15 | 2022 | |
| Medicem INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deidra Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.